# A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

> **NCT07287644** · PHASE2,PHASE3 · RECRUITING · sponsor: **Bluefin Biomedicine, Inc.** · enrollment: 210 (estimated)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **BIOLOGICAL:** BFB759
- **OTHER:** Placebo for BFB759

## Key facts

- **NCT ID:** NCT07287644
- **Lead sponsor:** Bluefin Biomedicine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07287644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07287644, "A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07287644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*